Filing Flows › Health Care › MeiraGTx Holdings (MGTX)
MeiraGTx Holdings (MGTX) earnings and revenue breakdown
Latest: Q2 2026 · 10-Q filed Aug 13, 2026 · MeiraGTx Holdings (MGTX) Q2 2026 earnings results →
Q2 2026 Revenue up 8609% year over year to $321M · 50¢ of every $1 of revenue kept as net profit · operating margin 76.0%
MeiraGTx Holdings made $321M in Q2 2026 (87× Y/Y): License revenue $205M, Service revenue - related party $105M, Service revenue $11.9M. Operating margin 76.0%, net earnings $161M. See where every dollar goes — costs, profit and cash — as a Sankey from the 10-Q filed Aug 13, 2026.
Drawing the Sankey…
Open the interactive Sankey → click any line for what the company wrote about it, compare Y/Y and Q/Q, export as PNG or PDF
What changed this quarter
Revenue was $321.4M in Q2 2026, up 8609% year over year and up 109604% from the previous quarter. License revenue was the largest line at 64% of revenue. Service revenue - related party added $101.2M year over year (up 2742%), 32% of the total change.
Operating profit was $244.4M, a 76.0% margin (up 1289.6 points year over year). Total costs grew 59% against revenue growth of 8609%. The fastest-growing cost line was Research & development (+73%). Net earnings were $160.7M. The effective tax rate was 1.4%.
Operating cash flow was −$38.5M. Non-cash charges added back $2.8M of depreciation and amortization and $3.8M of share-based compensation. Working capital and other items used $205.8M. Capital expenditures of $332K exceeded it, leaving free cash flow of −$38.9M.
Quarterly history
| Quarter | Form | Filed | Revenue | Y/Y | Op. margin | Net earnings | Op. cash flow |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 10-Q | Aug 13, 2026 | $321M | 87× | 76.0% | $161M | −$38.5M |
| Q1 2026 | 10-Q | May 14, 2026 | $293K | -85% | n/m | −$46.3M | $17.8M |
| Q4 2025 | 10-K | Mar 30, 2026 | $75.4M | +252% | 35.1% | $15.1M | $46.6M |
| Q3 2025 | 10-Q | Nov 13, 2025 | $410K | -96% | n/m | −$50.5M | −$12.2M |
| Q2 2025 | 10-Q | Aug 14, 2025 | $3.7M | 13× | n/m | −$38.8M | −$43.9M |
| Q1 2025 | 10-Q | May 13, 2025 | $1.9M | +176% | n/m | −$40.0M | −$36.8M |
| Q4 2024 | 10-K | Mar 13, 2025 | $21.4M | +948% | -147.2% | −$39.4M | −$23.3M |
Charts
Interactive views
The same charts as the app — open one to draw it.
💵Where each $1 goesinteractive
Loading the interactive chart…
🌏Named in Asian annual reportsinteractive
Loading the interactive chart…
🔄Rotation against the market and its industry (RRG)interactive
Loading the interactive chart…
🔍Earnings qualityinteractive
Loading the interactive chart…
⚖️Fair value by methodinteractive
Loading the interactive chart…
🔭Outlook & guidanceinteractive
Loading the interactive chart…
📈Investments: gains and what it boughtinteractive
Loading the interactive chart…
🏭Its industry’s money flow (input-output)interactive
Loading the interactive chart…
About MeiraGTx Holdings
We are a vertically integrated, clinical-stage genetic medicines company with a broad pipeline of late-stage clinical programs, including radiation-induced xerostomia, Parkinson’s disease and AIPL1-associated retinal dystrophy. Our clinical programs use targeted local delivery of small doses of genetic medicines to treat both inherited and more common conditions with severe unmet need. The successful development of the clinical pipeline is supported by our internal end-to-end manufacturing capabilities. We have two viral vector production facilities for good manufacturing practices, or GMP, internal plasmid production for GMP, as well as an in-house Quality Control hub for stability and release, all fit for Investigational New Drug application (IND) through commercial supply.
In its own words, from its 10-K, filed Mar 30, 2026.
MeiraGTx Holdings against its Biological Products, (No Diagnostic Substances) peers
The largest companies of the same SEC industry, each at its latest quarter. Revenue growth: 87× against the peers' median +11%. Operating margin: 76.0% against the peers' median 35.8%.
| Company | Quarter | Revenue | Y/Y | Op. margin |
|---|---|---|---|---|
| MGTX MeiraGTx Holdings | Q2 2026 | $321M | 87× | 76.0% |
| AMGN Amgen | Q3 2026 | $10.4B | +8% | 35.8% |
| GILD Gilead Sciences | Q3 2026 | $8.3B | +7% | 41.7% |
| BIIB Biogen | Q3 2026 | $2.8B | +11% | -0.3% |
| MRNA Moderna | Q3 2026 | $1.3B | +29% | 9.9% |
| NBIX Neurocrine Biosciences | Q3 2026 | $1.1B | +41% | 29.5% |
| EXEL Exelixis | Q3 2026 | $659M | +10% | 40.8% |
| HALO Halozyme Therapeutics | Q3 2026 | $493M | +39% | 59.8% |
| TECH Bio-Techne | Q1 FY27 | $300M | +5% | 12.2% |
Source: MeiraGTx Holdings 10-Q on SEC EDGAR · CIK 1735438 · Biological Products, (No Diagnostic Substances)
More on MGTX
History
Every quarter: Q2 2026 results · Q1 2026 results · Q4 2025 results · Q3 2025 results · Q2 2025 results · Q1 2025 results · Q4 2024 results